Search Results

Ancora Heart, Inc. and egnite, Inc. today announced a strategic partnership to accelerate clinical trial enrollment for Ancora Heart’s CORCINCH-HF pivotal clinical trial, which is evaluating the safety and efficacy of the AccuCinch® Ventricular Restoration System.

Ancora Heart, Inc today announced that patients treated with the investigational AccuCinch ® Ventricular Restoration System demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart.

Ancora Heart, Inc. today announced that a late-breaking clinical science presentation featuring the latest data from studies of the investigational AccuCinch ® Ventricular Restoration System will take place at the upcoming Technology and Heart Failure Therapeutics conference (THT 2023).

Ancora Heart, Inc. , a company developing a novel device-based therapy to address heart failure (HF), today announced that David J. Tucker has joined the company as chief financial officer.

Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch ® Ventricular Restoration System.

Ancora Heart, Inc. a company developing a novel device-based therapy to address heart failure (HF), today announced that Mark Miles has joined the company as Chief Commercial Officer (CCO).

Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), has entered a term sheet to acquire Ancora Medical Inc. (“Ancora”), a privately held medical technology company with anchoring catheter and needle combo technology that was approved by the FDA in February 2020.

Aspero Medical had previously received clearance from the Food and Drug Administration (FDA) to market and sell the Ancora-SB small bowel balloon overtube which incorporates the company’s patented Pillar micro-texture balloon technology.

Ancora Heart AccuCinch ® System Shows Positive 12-Month Outcomes in Multi-Study Analysis

Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure, today announced its activities at the upcoming, first ever Technology and Heart Failure Therapeutics conference (THT 2022), which is produced by the Cardiovascular Research Foundation (CRF) and will be held February 1-2 at the New York Marriott Marquis.